{
  "source": "PA-Med-Nec-Dojolvi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2221-6\nProgram Prior Authorization/Medical Necessity\nMedication Dojolvi® (triheptanoin)\nP&T Approval Date 10/2020, 12/2020, 5/2022, 5/2023, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nDojolvi (triheptanoin) is a medium-chain triglyceride indicated as a source of calories and fatty\nacids for the treatment of pediatric and adult patients with molecularly confirmed long-chain\nfatty acid oxidation disorders (LC-FAOD).\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Dojolvi will be approved based on all of the following criteria:\na. Submission of medical records confirming the diagnosis of long-chain fatty acid\noxidation disorders (LC-FAOD) with at least two of the following diagnostic criteria:\n(1) Disease specific elevation of acylcarnitines on a newborn blood spot or in\nplasma\n(2) Low enzyme activity in cultured fibroblasts\n(3) Genetic testing demonstrating one or more pathogenic mutations in a gene\nassociated with long-chain fatty acid oxidation disorders (e.g., CPT2,\nACADVL, HADHA, or HADHB)\n-AND-\nb. Patient is not receiving Dojolvi in combination with any other medium-chain\ntriglyceride (MCT) products\n-AND-\nc. Prescribed by a board-certified medical geneticist experienced in the treatment of\nlong-chain fatty acid oxidation disorders (LC-FAOD)\n-AND-\nd. Target recommended daily dosage does not exceed 35% of the patient’s total\nprescribed daily caloric intake (DCI)\n-AND-\ne. Patient is receiving disease related dietary management\n© 2025 UnitedHealthcare Services Inc.\n1\n-AND-\nf. If not diagnosed by newborn screening, patient has a history of clinical manifestations\nof long-chain fatty acid oxidation disorders LC-FAOD (e.g., rhabdomyolysis)\nAuthorization will be issued for 12 months\nB. Reauthorization\n1. Dojolvi will be approved based on all of the following criteria:\na. Documentation of positive clinical response to Dojolvi therapy (e.g., increased\ncardiac efficiency, decreased left ",
    "authorization\n1. Dojolvi will be approved based on all of the following criteria:\na. Documentation of positive clinical response to Dojolvi therapy (e.g., increased\ncardiac efficiency, decreased left ventricular wall mass, decreased incidence of\nrhabdomyolysis, etc.)\n-AND-\nb. Patient is not receiving Dojolvi in combination with any other medium-chain\ntriglyceride (MCT) product\n-AND-\nc. Prescribed by a board-certified medical geneticist experienced in the treatment of\nlong-chain fatty acid oxidation disorders (LC-FAOD)\n-AND-\nd. Target recommended daily dosage does not exceed 35% of the patient’s total\nprescribed daily caloric intake (DCI)\n-AND-\ne. Patient is receiving disease related dietary management\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n© 2025 UnitedHealthcare Services Inc.\n2\n4. References:\n1. Dojolvi [package insert]. Novato, CA: Ultragenyx Pharmaceutical, Inc.; October 2023.\n2. Merritt JL 2nd, Norris M, Kanungo S. Fatty acid oxidation disorders. Ann Transl Med.\n2018;6(24):473. doi:10.21037/atm.2018.10.57\n3. Knottnerus SJG, Bleeker JC, Wüst RCI, et al. Disorders of mitochondrial long-chain fatty acid\noxidation and the carnitine shuttle. Rev Endocr Metab Disord. 2018;19(1):93-106.\ndoi:10.1007/s11154-018-9448-1\nProgram Prior Authorization/Medical Necessity – Dojolvi® (triheptanoin)\nChange Control\nDate Change\n10/2020 New program\n12/2020 Change to prescriber requirement criteria.\n5/2022 Annual review with no change ",
    "m Prior Authorization/Medical Necessity – Dojolvi® (triheptanoin)\nChange Control\nDate Change\n10/2020 New program\n12/2020 Change to prescriber requirement criteria.\n5/2022 Annual review with no change to clinical criteria. Updated reference.\n5/2023 Annual review with no change to clinical criteria.\n5/2024 Annual review. Revised listing of genes associated with long-chain\nfatty acid disorders. Revised initial authorization to 12 months. Updated\nreferences.\n5/2025 Annual review with no change to clinical criteria.\n© 2025 UnitedHealthcare Services Inc.\n3"
  ]
}